A prospective and retrospectice, non-interventional observational study for efficacy and safety of Atazanavir/Ritonavir of HIV-infected woman

A prospective and retrospectice, non-interventional observational study for efficacy and safety of Atazanavir/Ritonavir of HIV-infected woman - ATASAFE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00000306

Enrollment

140

Registered

2010-01-15

Start date

2010-03-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B24

Interventions

Group 1:

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: * Woman * equal to or greater than 18 years * HIV 1 positive * Atazanavir/Ritonavir HAART at least 3 months * Readiness to operate effective contraception during treatment

Exclusion criteria

Exclusion criteria: * Pregnant woman * Known contraindication against Atazanavir and Ritonavir

Design outcomes

Primary

Measure	Time frame
Time to virological failure and treatment discontinuation Definied as: - Loss to follow-up - Drop-out - Change of treatment due to intolerance ot toxicity - Virological failure, defined as viral load > 400c/ml - Clinical progression defined as apperance of a new AIDS event after the first month of treatment or death	—

Secondary

Measure	Time frame
Detection of adverse drug reactions	—

Countries

Germany

Contacts

Public ContactNorbert H. Brockmeyer

Ruhr-Universität Bochum Klinik für Dermatologie und Allergologie Kompetenznetz HIV/AIDS

n.brockmeyer@derma.de+49 (0) 234 509 -3471

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026